Trial Profile
A Study of Obinutuzumab in Combination With High-Dose Methylprednisolone in Chronic Lymphocytic Leukemia Patients
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 20 Jul 2020
Price :
$35
*
At a glance
- Drugs Obinutuzumab (Primary) ; Methylprednisolone
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions; Therapeutic Use
- 15 Jul 2020 Planned End Date changed from 1 May 2022 to 25 Dec 2025.
- 15 Jul 2020 Planned primary completion date changed from 1 May 2020 to 30 Oct 2025.
- 15 Jul 2020 Status changed from completed to active, no longer recruiting.